ON Spindel… - Arteriosclerosis, Thrombosis, and Vascular …, 2011 - Am Heart Assoc Methods and Results— In response to physiological levels of ROS (10 ng/mL tumor necrosis factor-α and 30 µmol/LH 2 O 2 ), TXNIP-TRX1 translocated to the plasma membrane in human umbilical vein EC, with a peak at 30 minutes, as measured by immunofluorescence ... All 2 versions
[HTML] from jcojournal.orgNJ Robert, V Diéras, J Glaspy… - Journal of Clinical …, 2011 - jcojournal.org ... Antiangiogenic therapies such as bevacizumab (BV), an antibody to vascular endothelial growth factor, have proven to be effective in improving ... the effectiveness of taxane (Tax) plus BV combinations in the initial treatment of human epidermal growthfactorreceptor 2 (HER2 ... Cited by 156 - Related articles - All 7 versions
K Kisko, MS Brozzo, J Missimer, T Schleier… - The FASEB Journal, 2011 - FASEB ABSTRACT Receptor tyrosine kinases play essential roles in tissue development and homeostasis, and ab- errant signaling by these molecules is the basis of many diseases. Understanding the activation mechanism of these receptors is thus of high clinical relevance. We ... Related articles - All 2 versions
H Noma, H Funatsu, T Mimura, S Eguchi… - American Journal of …, 2011 - Elsevier BRVO patients had a significantly higher vitreous fluid level of sVEGFR-2 (median, 1670 pg/mL; interquartile range [IQL], 1205 to 2225 pg/mL) than macular hole patients (median, 1265 pg/mL; IQR, 731 to 1800 pg/mL; P = .017), as was the case for VEGF (median, 237 pg/mL; ... Related articles - All 3 versions
[HTML] from 171.66.121.246JR Hecht, T Trarbach, JD Hainsworth… - Journal of Clinical …, 2011 - 171.66.121.246 Patients and Methods Patients (N = 1,168) with previously untreated metastatic colorectal cancer were randomly assigned 1:1 to receive FOLFOX4 plus PTK/ZK or placebo (ClinicalTrials.gov identifier: NCT00056459). Stratification factors included WHO performance status (0 v 1 ... Cited by 3 - Related articles - All 6 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
